FY2027 Earnings Forecast for Masimo Issued By Zacks Research

Masimo Co. (NASDAQ:MASI) – Investment analysts at Zacks Research issued their FY2027 EPS estimates for Masimo in a report issued on Tuesday, March 18th. Zacks Research analyst I. Bandyopadhyay anticipates that the medical equipment provider will post earnings of $6.61 per share for the year. The consensus estimate for Masimo’s current full-year earnings is $4.10 per share.

MASI has been the subject of several other research reports. Piper Sandler raised their price objective on Masimo from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Raymond James lifted their price target on Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a research report on Friday, December 27th. Wells Fargo & Company lifted their price target on Masimo from $193.00 to $205.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $190.00 price target (up previously from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research report on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, Masimo presently has a consensus rating of “Moderate Buy” and a consensus target price of $194.80.

Masimo Stock Performance

Shares of Masimo stock opened at $169.50 on Thursday. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $9.14 billion, a P/E ratio of 116.90 and a beta of 1.04. The business has a fifty day simple moving average of $175.00 and a two-hundred day simple moving average of $158.86. Masimo has a 12 month low of $101.61 and a 12 month high of $194.88.

Masimo (NASDAQ:MASI) last released its quarterly earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.42 by $0.38. The business had revenue of $600.70 million for the quarter, compared to analysts’ expectations of $593.35 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%.

Institutional Investors Weigh In On Masimo

A number of large investors have recently made changes to their positions in the company. Smartleaf Asset Management LLC grew its stake in shares of Masimo by 31.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider’s stock valued at $42,000 after purchasing an additional 60 shares during the period. EverSource Wealth Advisors LLC grew its stake in shares of Masimo by 40.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider’s stock valued at $37,000 after purchasing an additional 64 shares during the period. Blue Trust Inc. grew its stake in shares of Masimo by 56.3% during the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock valued at $33,000 after purchasing an additional 71 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its stake in shares of Masimo by 0.8% during the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,815 shares of the medical equipment provider’s stock valued at $1,622,000 after purchasing an additional 82 shares during the period. Finally, Thrivent Financial for Lutherans grew its stake in shares of Masimo by 0.8% during the 4th quarter. Thrivent Financial for Lutherans now owns 10,456 shares of the medical equipment provider’s stock valued at $1,728,000 after purchasing an additional 83 shares during the period. 85.96% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director Craig B. Reynolds sold 2,053 shares of Masimo stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $166.13, for a total value of $341,064.89. Following the completion of the sale, the director now directly owns 16,581 shares in the company, valued at approximately $2,754,601.53. This trade represents a 11.02 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Bilal Muhsin sold 30,000 shares of Masimo stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $167.49, for a total value of $5,024,700.00. Following the completion of the sale, the chief operating officer now owns 24,172 shares of the company’s stock, valued at $4,048,568.28. The trade was a 55.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 9.70% of the stock is owned by corporate insiders.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.